Xilio Therapeutics
Develops masked immuno-oncology therapies designed to activate within tumors.
$9.02
After-hours close−0.08 (−0.82%)
At close$9.10(+1.96%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 39.84%2.62M sharesInsiders 0.58%37.8K sharesOther 59.58%3.92M shares
Shares outstanding 6.58M · Float 2.36M · 35.8% free float
A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.
Institutions13F, as of Mar 31, 2026
24 holders · 2.62M shares
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664.0K | 10.10% | May 15, 2026 | |
| Gilead Sciences, Inc. | 650.4K | 9.89% | May 8, 2026 | |
| Frazier Life Sciences Management, L.P. | 422.5K | 6.43% | May 15, 2026 | |
| Sio Capital Management, LLC | 152.5K | 2.32% | May 14, 2026 | |
| Vanguard Capital Management LLC | 123.7K | 1.88% | May 15, 2026 | |
| Caligan Partners LP | 112.1K | 1.71% | May 15, 2026 | |
| Merck & Co., Inc. | 106.0K | 1.61% | May 13, 2026 | |
| Stonepine Capital Management, LLC | 64.2K | 0.98% | May 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 19.90% | 13G | Feb 12, 2026 ↗ | |
| GKCC, LLCincl. Yekaterina Chudnovsky | 15.90% | 13G | Sep 27, 2024 ↗ | |
| BCLS II Equity Opportunities, LP | 9.99% | 664.0K | 13G | May 15, 2026 ↗ |
| Orbimed Advisors LLC | 9.99% | 642.0K | 13G | May 15, 2026 ↗ |
| Coastlands Capital LP | 9.99% | 13G | Dec 11, 2025 ↗ | |
| Sirenia Capital Management LP | 9.90% | 1.14M | 13G | May 15, 2026 ↗ |
| AbbVie Inc. | 9.00% | 13G | Feb 18, 2025 ↗ | |
| StemPoint Capital LP | 8.40% | 13G | Feb 17, 2026 ↗ | |
| Frazier Life Sciences Public Fund, L.P. | 6.70% | 13G | Feb 13, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Rene Russo | director, officer: PRESIDENT AND CEO | 23.2K | 0.35% | Jan 5, 2026 |
| James Samuel Shannon | director | 10.0K | 0.15% | Mar 30, 2026 |
| Katarina Luptakova | officer: CHIEF MEDICAL OFFICER | 2.4K | 0.04% | Jan 5, 2026 |
| Christopher James Frankenfield | officer: Chief Financial Officer | 1.8K | 0.03% | Jan 5, 2026 |
| Kevin M. Brennan | officer: SVP, FINANCE AND ACCOUNTING | 455 | 0.01% | Jan 5, 2026 |
18 ten-percent owners hold 1.83M shares by Form 4, outside the officers-and-directors figure above · 2 people have not refiled in the last 18 months (1.1K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 26, 2026 | James Samuel Shannondirector | Purchase | 5,000 | $8.79 | 10,000 |
| Feb 13, 2026 | Gilead Sciences, Inc.10 percent owner | Purchase | 3,739,000 | $0.0001 | 40,384,266 |
| Jan 2, 2026 | Christopher James Frankenfieldofficer: Chief Financial Officer | Sale | 7,030 | $0.6432 | 24,766 |
| Jan 2, 2026 | Kevin M. Brennanofficer: SVP, FINANCE AND ACCOUNTING | Sale | 1,826 | $0.6432 | 6,371 |
CongressHouse and Senate disclosures
Not reported.